請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68869
標題: | 利用次世代定序技術建立藥物基因體學之基因檢測平台 Establishment of pharmacogenomics testing platform based on next-generation sequencing |
作者: | Yu-Shi Liu 劉昱希 |
指導教授: | 陳沛隆(Pei-Lung Chen) |
關鍵字: | 藥物基因體學,藥物動力學/藥效學,個人化醫療,次世代定序,臺灣人體生物資料庫, Pharmacogenomics,PK/PD,precision medicine,Next-generation sequencing (NGS),Leiden Open Variation Database (LOVD),Taiwan Biobank, |
出版年 : | 2017 |
學位: | 碩士 |
摘要: | Medical drugs show different efficacy and/or adverse drug reactions (ADRs) on patients. This is mostly due to the variations of DNA sequence. Pharmacogenomics is the study and applications about how genetic variations in individuals influence the drug response, which is composed of both pharmacokinetics and pharmacodynamics. Pharmacogenomics plays an important role in optimal drug choice and drug dosing. There are numerous genes involved in pharmacogenomics, which imposes a big challenge because of the complexity and high cost using conventional techniques like Sanger sequencing. In the present study, we set up a genetic testing platform through capture-based target enrichment followed by next-generation sequencing (NGS). Our panel covered approximately 345 major pharmacogenomics genes, including pharmacokinetics genes (for example, ADME genes regarding to absorption, distribution, metabolism and excretion) and pharmacodynamics genes, such as ABCB1, CFTR, CYPs, DRYP, EGFR, HLAs, KRAS, NAT2, RYR1, TPMT, UGT1A1 and VKORC1. A great proportion of our genes overlapped with those listed on FDA labeled biomarkers, Pharmacogenomics Knowledgebase (PharmGKB) and PharmaADME. We applied this panel to 34 individuals, including 6 controls with whole genome sequencing data from Taiwan Biobank for technical validation and 28 patients recruited from NTUH, trying to find specific ADR gene biomarkers. Also, we used LOVD (Leiden Open Variation Database) system to build a pharmacogenomics database in a uniform table format contains information on gene, variant, and drug response according to the PharmGKB clinical annotation file of warfarin, dabigatran, rivaroxaban, oxaliplatin and paclitaxel. In conclusion, the NGS-based pharmacogenomics panel and the pharmacogenomics LOVD database could be beneficial for precision medicine in clinical applications and academic research. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68869 |
DOI: | 10.6342/NTU201703406 |
全文授權: | 有償授權 |
顯示於系所單位: | 基因體暨蛋白體醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 2.81 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。